CXCR2 and familial pancreatic carcinoma: Furthermore, Zhang et al. proposed that IFN-γ may be a good therapeutic option for improving the efficacy of PD-1 blockade therapy for pancreatic cancer by preventing the trafficking of CXCR2+ CD68+ immunosuppressive macrophages to the TME by blocking the CXCL8-CXCR2 axis [109].